Skip to main content
Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc. — Investor Relations & Filings

Ticker · LUCD ISIN · US54948X1090 US Human health and social work activities
Open in API
Filings indexed 250 across all filing types
Latest filing 2026-05-14 Earnings Release
Country US United States of America
Listing US LUCD

About Lucid Diagnostics Inc.

https://www.luciddx.com/

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the prevention of esophageal cancer. The company's primary product is the EsoGuard Esophageal DNA Test, a non-invasive diagnostic tool designed for the early detection of esophageal precancer, including Barrett's esophagus. Utilizing targeted next-generation sequencing (NGS) technology, EsoGuard analyzes DNA biomarkers from cells collected in a simple, office-based procedure. This allows for the screening of at-risk patients, such as those with chronic gastroesophageal reflux disease (GERD), without the need for an initial endoscopy. The company aims to improve patient outcomes by identifying precancerous conditions at a treatable stage, thereby preventing the progression to esophageal adenocarcinoma.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 92% confidence The document is a Form 8-K “Current Report” under the Securities Exchange Act, specifically furnishing a press release under Item 2.02 titled “Results of Operations and Financial Condition” announcing financial results for the fiscal quarter ended March 31, 2026. It attaches the press release as Exhibit 99.1, which constitutes the initial announcement of quarterly financial results (key highlights only). This matches the definition of an Earnings Release (Code: ER). Q1 2026
2026-05-14 English
10-Q - Lucid Diagnostics Inc. (0001799011) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
ARS - Lucid Diagnostics Inc. (0001799011) (Filer)
Annual Report
2026-04-30 English
424B5 - Lucid Diagnostics Inc. (0001799011) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to an offering of 18,000,000 shares of common stock by Lucid Diagnostics Inc. It includes detailed information about the offering price, underwriting discounts, risk factors, use of proceeds, capitalization, dilution, and legal matters. The document is a formal registration and offering document used to raise capital through the issuance of new shares. This type of document is best classified as a Capital/Financing Update (CAP) because it provides updates on company fundraising and financing activities, specifically a public offering of common stock. It is not an annual or quarterly report, audit report, earnings release, or any other category. The length and content confirm it is a full prospectus supplement, not merely an announcement or regulatory filing.
2026-04-23 English
EFFECT - Lucid Diagnostics Inc. (0001799011) (Filer)
Regulatory Filings
2026-03-27 English
424B5 - Lucid Diagnostics Inc. (0001799011) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It relates to an 'at the market offering' of common stock by Lucid Diagnostics Inc. The text includes detailed information about the offering, the sales agreement with Maxim Group LLC, risk factors, use of proceeds, dilution, and other offering-specific details. This type of document is a capital raising disclosure, specifically a prospectus supplement for a securities offering. It is not an annual report, earnings release, or any other financial report type. It is clearly a Capital/Financing Update as it provides details on the company's equity offering and related financing activities.
2026-03-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.